Clinical Trial: AST-120 Used to Treat Mild Hepatic Encephalopathy
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the T
Brief Summary: The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.
Detailed Summary:
Sponsor: Ocera Therapeutics
Current Primary Outcome: Neurocognitive improvement, defined as the change in the global summary score of the RBANS at Week 8 compared to Baseline. [ Time Frame: 8 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Ocera Therapeutics
Dates:
Date Received: March 20, 2009
Date Started: March 2009
Date Completion:
Last Updated: June 2, 2014
Last Verified: June 2014